Providing Scholarships, Class Reunion Assistance, and More...

With 58 of 78 ALK+ patients giving an answer to treatment.

Brigatinib drug displays promise against ALK+ non-small cell lung cancer in phase I/II clinical trial Phase We/II clinical trial results reported in the American Culture for Clinical Oncology Annual Meeting 2015 present promising outcomes for investigational drug brigatinib against ALK+ non-small cell lung tumor , with 58 of 78 ALK+ patients giving an answer to treatment, including 50 of 70 sufferers who had progressed after earlier treatment with crizotinib, the 1st licensed ALK inhibitor. Progression-free survival in patients previously treated with crizotinib was 13 modafinilreview.net/adhd-and-modafinil.html .4 months.

for insomnia

Breathe Technologies earns Medical Design Excellence Award for NIOV System Breathe Technologies, Inc. It is designed to facilitate ambulation for adult individuals with respiratory insufficiency. ‘Breathe is definitely honored to have already been selected as a Winner of a 2012 Medical Design Excellence Awards. To be recognized by MDEA underscores the unique and innovative aspects of the Breathe NIOV Program. We believe our technology has the potential to allow patients with respiratory insufficiency to experience greater flexibility and participation in actions of daily living,’ stated Larry Mastrovich, Breathe Systems, CEO and President.